


## AUTOLOGOUS ANTITUMOR VACCINE



AAV appearance

### Areas of Application

The vaccine is used for cancer biotherapy. The inclusion of antitumor autovaccine (AAV) into the therapeutic regimen of oncology patients enables preventing the development of metastasis and disease recurrence, increasing the survival rates, and improving their quality of life




Overall survival of colorectal cancer patients (Kaplan-Meier test)

### Specification

The vaccine contains biotechnologically-modified (through the use of metabolism products of *Bacillus subtilis* B-7025) tumor antigens of autologous tumor

### Advantages

There are no analogs of AAV. Suitable for the treatment of patients with various tumors. The vaccine has been tested in some oncological clinics in Ukraine and is prepared to be included into the standards for treatment of oncology patients. The AAV is well tolerated, nontoxic, and easy-to-use



Overall survival of breast cancer patients (Kaplan-Meier test)

### Stage of Development. Suggestion for Commercialization

IRL7, TRL7  
Seeking investors for getting license.  
Manufacture of AAV with patient material, upon request

### IPR Protection

IPR1, IPR3

### Contact Information

Tatiana V. Pyatchanina, RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of the NAS of Ukraine; +38 044 259 01 67, e-mail: tanya\_pyatchanina@ukr.net